Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

NCT02616562 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02616562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
September 26, 2024
Enrollment
76 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency in children, growth hormone disorder